<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114775</url>
  </required_header>
  <id_info>
    <org_study_id>13-0324</org_study_id>
    <nct_id>NCT02114775</nct_id>
  </id_info>
  <brief_title>Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)</brief_title>
  <official_title>Growth Hormone or Sildenafil as Therapies for Fatigue in MTBI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal is to determine whether perceptual or performance fatigue can be reduced in&#xD;
      MTBI patients with and without growth hormone (GH) deficiency by treating them in a crossover&#xD;
      fashion based upon GH status.&#xD;
&#xD;
      A battery of functional, fatigue, cognitive, imaging and blood flow tests will be performed&#xD;
      to assess the efficacy of the two drug interventions, Growth hormone and Sildenafil.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three primary outcome measures are proposed:&#xD;
&#xD;
        1. Perceptual fatigue as measured weekly using the Brief Fatigue Inventory (BFI) (59).&#xD;
&#xD;
        2. Performance fatigue as measured at baseline and month 3, 6 and 12 using hand and leg&#xD;
           dynamometry.&#xD;
&#xD;
        3. Neuropsychological function as measured at baseline and month 12.&#xD;
&#xD;
      Secondary outcomes will include:&#xD;
&#xD;
        1. Modified 6 minute walk performance as measured at baseline, and month 3, 6 and 12.&#xD;
&#xD;
        2. Mood and quality of life using the Profile of Mood States, Quality of Life Assessment of&#xD;
           GH Deficiency in Adults questionnaire, and a grief assessment (60) (POMS), measured at&#xD;
           baseline, and month 3, 6, and 12.&#xD;
&#xD;
        3. Sleep quality using the Pittsburgh Sleep Quality Index (PSQI), baseline, and month 3, 6,&#xD;
           and 12.&#xD;
&#xD;
        4. Multidimensional fatigue using Multidimensional Fatigue Symptom Inventory (MFSI) at&#xD;
           baseline, and month 3, 6 and 12.&#xD;
&#xD;
        5. Skeletal muscle mass, as derived from lean body mass determinations, using dual energy&#xD;
           X-ray absorptiometry (iDEXA) at baseline, and month 3, 6, and 12.&#xD;
&#xD;
        6. Physical Activity, measured daily using accelerometry.&#xD;
&#xD;
        7. Cerebral blood oxygen saturation measured at baseline and month 12.&#xD;
&#xD;
        8. Leg blood flow measured at baseline, and month 3, 6 and 12.&#xD;
&#xD;
        9. Blood Hormones at baseline and month 3, 6 and 12.&#xD;
&#xD;
       10. Characterization of brain tissue using structural, &quot;resting state&quot; and diffusion&#xD;
           functional MR at baseline and month 3, 6, and 12.&#xD;
&#xD;
       11. Indirect calorimetry measured at baseline and month 3, 6 and 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2014</start_date>
  <completion_date type="Actual">November 10, 2017</completion_date>
  <primary_completion_date type="Actual">November 10, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance fatigue as measured by using hand grip dynamometry at baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Hand grip exercises will be used to measure performance fatigue at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using hand grip dynamometry at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Hand grip exercises will be used to measure performance fatigue after 3 months of study intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using hand grip dynamometry at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Hand grip exercises will be used to measure performance fatigue after 6 months of study intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using hand grip dynamometry at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Hand grip exercises will be used to measure performance fatigue after 12 months of study intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using leg dynamometry at baseline</measure>
    <time_frame>baseline</time_frame>
    <description>Leg exercises will be used to measure performance fatigue at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using leg dynamometry at 3 months</measure>
    <time_frame>3 months</time_frame>
    <description>Leg exercises will be used to measure performance fatigue after 3 months of study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using leg dynamometry at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Leg exercises will be used to measure performance fatigue after 6 months of study intervention.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance fatigue as measured by using leg dynamometry at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Leg exercises will be used to measure performance fatigue after 12 months of study</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Recombinant Growth Hormone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double blind placebo/Genotropin cross over design for 6 months with cross over at 3 months. Then open label Genotropin from month 6 - 12.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Double blinded placebo/Sildenafil crossover design for 6 months with crossover at month 3. Then open label Sildenafil from months 6-12.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months</description>
    <arm_group_label>Recombinant Growth Hormone</arm_group_label>
    <other_name>Genotropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>50 mg by mouth daily</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <other_name>Viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study</description>
    <arm_group_label>Recombinant Growth Hormone</arm_group_label>
    <arm_group_label>Sildenafil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male or female with a diagnosis of mild TBI and 6 month post-injury. Age 18 to 60 years.&#xD;
        Complaint of fatigue, with score of 3 or greater on questions 1, 2, or 3 of the Brief&#xD;
        Fatigue Inventory.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria (general)&#xD;
&#xD;
          1. Significant heart, liver, kidney, blood or respiratory disease.&#xD;
&#xD;
          2. Active coronary disease.&#xD;
&#xD;
          3. Pregnancy.&#xD;
&#xD;
          4. Alcohol or drug abuse.&#xD;
&#xD;
          5. Unable to walk unassisted.&#xD;
&#xD;
          6. Diabetes mellitus and anterior pituitary abnormalities diagnosed upon screening.&#xD;
&#xD;
          7. Premorbid history of psychiatric disorder.&#xD;
&#xD;
          8. Premorbid history of head trauma.&#xD;
&#xD;
        Exclusion criteria (sildenafil/placebo group)&#xD;
&#xD;
          1. Use of nitrates.&#xD;
&#xD;
          2. Use of alpha blockers.&#xD;
&#xD;
          3. Systolic blood pressure &lt;100 or &gt;150, diastolic blood pressure &lt;60 or &gt;90. This range&#xD;
             is smaller than the acceptable range stated in the prescribing information for&#xD;
             sildenafil (&gt;90/50 and &lt;170/110).&#xD;
&#xD;
          4. Peripheral vascular disease.&#xD;
&#xD;
          5. Use of a phosphodiesterase 5 inhibitor.&#xD;
&#xD;
        Exclusion criteria (growth hormone/placebo group)&#xD;
&#xD;
          1. Coumadin because of the risk of bleeding with daily injections of Recombinant Human&#xD;
             Growth Hormone (rhGH) in the growth hormone (GH) arm of the study.&#xD;
&#xD;
          2. Subjects who are deficient in cortisol or thyroid at screening will be excluded until&#xD;
             hormone abnormalities have been corrected.&#xD;
&#xD;
          3. Subjects with chronic pain who are being managed with narcotics will be excluded as&#xD;
             the effects of central nervous system depressants may interfere with study test&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall J Urban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melinda Sheffield-Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brent Masel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transitional Learning Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mild traumatic brain injury</keyword>
  <keyword>growth hormone</keyword>
  <keyword>fatigue</keyword>
  <keyword>sildenafil</keyword>
  <keyword>neurology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Brain Concussion</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

